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Abstract—Herein we report the synthesis and biological evaluation of some potent and selective 
A1 adenosine receptor agonists, which incorporate a functionalised linker attached to an antioxidant 
moiety.  N6-(2,2,5,5-Tetramethylpyrrolidin-1-yloxyl-3-ylmethyl)adenosine (VCP28, 2e) proved to 
be an agonist with high affinity (Ki = 50 nM) and good selectivity for the A1 adenosine receptor.  
N6-[4-[2-[1,1,3,3-Tetramethylisoindolin-2-yloxyl-5-amido]ethyl]phenyl]adenosine (VCP102, 5a) 
has higher binding affinity (Ki = 7 nM), but lower selectivity (A3/A1 = ~3).  All compounds bind 
weakly (Ki > 1 µM) to A2A and A2B receptors.  The combination of A1 agonist activity and anti-
oxidant activity has the potential to produce cardioprotective effects. 
The cardioprotective effects of adenosine are well established, and are the basis for a variety of 
therapeutic strategies.  Adenosine is a key player in the phenomenon of “preconditioning”, a large 
number of studies in the early 1990’s reported a process in which a prior instance of ischaemia 
protects the heart from future ischaemic events, and that adenosine re-uptake inhibitors could 
increase the level of protection.1-3  More recently, the focus of attention has moved to the protectant 
effects of adenosine from reperfusion injury when adenosine is released (or administered) during 
and/or after a period of ischaemia.4  The “Acute myocardial Infarction STudy of ADenosine 
(AMISTAD)” examined the effects of adenosine (administered to patients with thrombolytic 
therapy) within a few hours of myocardial infarction and reported a reduction in infarct size.5,6  
Cardioprotection has been shown in animal models to occur after activation of any of the four 
adenosine receptor subtypes, A1, A2A, A2B A3 receptors.7-11.  The greatest body of work has been 
performed on the A1 receptor subtype, and a variety of mechanisms have been elucidated.  
Activation of A1 adenosine receptors activation results in inhibition of adenylyl cyclase and 
consequent decreases in cAMP as well as signal transduction events mediated by the release of βγ 
G protein subunits.  The protective effects of adenosine A1 receptor activation occur via several 
mechanisms, including activation of the protein kinase C / erk pathway and opening of 
mitochondrial K+ ATP channels.12,13 
 
Antioxidants produce cardioprotection by several mechanisms including direct scavenging of 
superoxide anion, the lynchpin radical in ischemia-reperfusion injury.  In addition, modulation of 
serum complement activity, as well as the reduction in the levels of C-reactive protein (CRP) and 
the membrane attack complex (MAC) in infarcted tissue suggest a significant antiinflammatory 
component in the mechanism of antioxidants.14  Exercise protects the heart in part by increasing the 
expression of antioxidant enzymes.15  In addition, isomers of vitamin E have cardioprotective 
effects that appear to be due to inhibition of c-Src activation and proteasome stabilization.16  
Furthermore, some drugs currently in clinical use, such as anti-hypertension reagents including 
angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and anti-
hyperlipidemic reagents like statins, may also protect the heart via antioxidant action in addition to 
their primary pharmacological effect.17,18 
 
We now report the design, synthesis and preliminary pharmacological evaluation of dual acting 
antioxidant A1 adenosine receptor agonists.  More specifically, known antioxidant moieties have 
been incorporated in the design of new A1 AR agonists with the view to enhancing receptor affinity 
and selectivity in addition to providing antioxidant activity. 
 
Adenosine analogs with alkyl, cycloalkyl, bicycloalkyl and aryl groups in the N6-position are 
generally known to be potent and selective A1AR agonists (in the absence of additional 
modifications).19  In a number of cases, the presence of a heteroatom in the N6-cycle further 
improved A1AR activity.  In our first series of target compounds a group with know antioxidant 
activity was incorporated directly in the N6-position.  These compounds were prepared via the 
reaction of 6-chloropurine riboside (1) with the appropriate amine in the presence of 
N,N-diisopropylethylamine (DIPEA).  These reactions provided the desired target compounds 2a-e 
in good to excellent yield, ranging from 71–89% (Scheme 1). 
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Scheme 1:  (i) R-NH2, N(i-Pr)2Et, t-BuOH, 83 °C. 
 
A second series of target compounds was prepared in which the antioxidant moiety was attached to 
the N6-position via an alkyl linker.  This initially involved the preparation of 
N6-(6-aminohexyl)adenosine (3), followed by an EDCI mediated coupling to connect the 
antioxidant group (Scheme 2).  Alkyl aryl linkers were also targeted as the interaction of a phenyl 
group with the N6-binding domain is known to enhance A1AR affinity and selectivity.19  In this 
approach the antioxidant moiety was first coupled to 4-(2-aminoethyl)aniline to afford the 
corresponding carboxamide of type 6.  The reaction of 6 with 6-chloropurine riboside afforded the 
desired N6-substituted adenosines (5a-b) in good yield (Scheme 2). 
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Scheme 2.  (i) H2N(CH2)6NH2, Et3N, EtOH, 78 °C; (ii) R-COOH, EDCI, HOBt, N(i-Pr)2Et, DMF, 
25 °C. 
 
Receptor Binding Assays: The receptor binding affinity of the initial series of compounds bearing a 
substituent known to confer antioxidant activity in the N6-position is described in Table 1.  All of 
the N6-nitroxide compounds (2a, 2c, 2e) had sub-micromolar Ki values at the A1AR and good 
selectivity versus A2AAR and the A2BAR.  Affinity for the A3AR ranged from very modest in the 
case of compound 2a to high for compound 2e.  Interactions between a nitroxide moiety and the N6-
binding domain of adenosine receptors not been explored to date.  In order to probe the effects of 
this group on A1AR and A3AR affinity and selectivity, analogs in which the nitroxide was replaced 
by the corresponding secondary amine were prepared and evaluated (Table 1, compounds 2b and 
2d).  A comparison of 2a with 2b and 2c with 2d suggests that the presence of a stable free radical 
in these positions is not deleterious for interaction with the A1 adenosine receptor. 
 
Table 1:  Receptor Affinity of the Target Compounds. 
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No. R A1 
Ki (μM) 
A2A 
Ki (μM) 
A2B 
Ki (μM) 
A3 
Ki (μM) 
2a 
N
O
 
0.10 ± 0.03 >10 μM >10 μM 0.79 ± 0.56 
2b 
NH
 
0.29 ± 0.03 >10 μM >10 μM 0.28 ± 0.17 
2c 
N O
 
0.05 ± 0.01 >10 μM >10 μM 8.56 ± 3.20 
2d 
NH
 
1.58 ± 0.45 >10 μM >10 μM 25.0 ± 6.40 
2e 
N
C
H2
O
 
0.05 ± 0.01 >10 μM >10 μM 21.2 ± 8.30 
4a 
N
O
 
0.015 ± 0.0003 >10 μM >10 μM 0.089 ± 0.031 
4b 
OH
 
0.040 ± 0.0003 >10 μM >10 μM 0.014 ± 0.048 
5a 
N
O
 
0.007 ± 0.001 >10 μM 1.45 ± 0.08 0.023 ± 0.01 
5b 
OH
 
0.032 ± 0.006 >10 μM 8.58 ± 0.90 0.084 ± 0.001 
 
Although it is well known that the N6-binding domain can accommodate a wide range of aryl and 
cycloalkyl groups, the incorporation of very bulky tetramethylisoindolin-2-yloxyl and 
tetramethylpiperidin-1-yloxyl groups in this position afforded agonists with modest affinity for the 
A1AR.  In order to improve receptor affinity, the antioxidant moiety was attached via an alkylamino 
linker.  Linkers of this type have previously proven to be effective in connecting A1 adenosine 
receptor agonists with fluorescent markers and also for the preparation of bivalent and bifunctional 
targets.20-22 
 
A functionalised linker was employed in order to achieve further improvements in A1AR affinity.  
This linker incorporated an N6-phenyl group to allow interaction with the hydrophobic region of the 
N6-binding domain, attached to 4-alkyl amino functionality which provided a handle for the 
attachment of the antioxidant group. 
 
Cardiomyocyte Model of Ischaemia: Cultured H9C2 embryonic rat atrial cardiomyocytes were 
exposed to conditions used previously to mimic in vivo ischaemia.  This type of ischaemic model 
produces necrotic and apoptotic cell death20, which results in membrane dysfunction and allows 
entry of propidium iodide.23  Under simulated ischaemia conditions, approximately 40% of all cells 
stained positively for propidium iodide (Figure 1 – the PI-positive cell number in the simulated 
ischaemia treatment was normalised to 100%).  When cells were incubated in the simulated 
ischaemia conditions in the presence of N6-cyclopentyladenosine (CPA, 10 nM), the number of PI-
positive cells was reduced by 86.18 ± 6.19 %, to a level similar to that seen in cells exposed to 
normal oxygenated media (control).  The series of adenosine receptor agonists tested in this assay 
all demonstrated cardioprotective properties at the same concentration (10 nM).  Compound 2e 
(84.84 ± 3.0 % reduction in dead cell number) demonstrated similar efficacy to CPA at this 
concentration, whilst compounds 5a (54.74 ± 19.89 % reduction in dead cell number) and 5b (73.24 
± 7.8% reduction in dead cell number) were less efficacious. 
  
 
Figure 1.  (a) The effects of adenosine receptor agonists on a cell model of ischaemia. 
Cells were grown in either normal medium (control) or hypoxic simulated ischaemia 
medium (all other treatments) for 12 hours.  Propidium iodide exclusion was then used 
to determine the number of viable cells, and cell death calculated for each treatment, 
with the simulated ischaemia treatment normalised to 100% (mean ± S.E.M., n = 3).      
(b) representative images from cells incubated as described in Figure 1 (a). 
 
These protective effects of CPA and analogs 2e, 5a and 5b were all significantly reduced in the 
presence of the adenosine A1 receptor antagonist 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX), 
over the range of agonist concentrations of 10-1000 nM (ANOVA, P<0.05). 
 
These data indicate that the adenosine receptor analogs evaluated have significant cardioprotective 
effects at low nanomolar concentrations.  The protective effects of the analogs were reduced but not 
abolished in the presence of the A1 receptor antagonist DPCPX, raising the possibility that there 
was some benefit derived from the anti-oxidant attachments.  We are currently investigating this 
potential cardioprotective mechanism further. 
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